• Incelldx Inc., of Menlo Park, Calif., said it entered a deal with Bristol-Myers Squibb Co., of New York, related to the development of an assay for potential application of a molecular companion diagnostic intended to identify patients likely to benefit from treatment with a BMS drug currently in development.